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Mesenchymal stem cells (MSCs) commonly defined
by in vitro functions have entered clinical application
despite little definition of their function in residence.
Here, we report genetic pulse-chase experiments
that define osteoblastic cells as short-lived and
nonreplicative, requiring replenishment from bone-
marrow-derived, Mx1+ stromal cells with ‘‘MSC’’
features. These cells respond to tissue stress and
migrate to sites of injury, supplying new osteoblasts
during fracture healing. Single cell transplantation
yielded progeny that both preserve progenitor func-
tion and differentiate into osteoblasts, producing
new bone. They are capable of local and systemic
translocation and serial transplantation. While these
cells meet current definitions of MSCs in vitro, they
are osteolineage restricted in vivo in growing and
adult animals. Therefore, bone-marrow-derived
MSCs may be a heterogeneous population with the
Mx1+ population, representing a highly dynamic
and stress responsive stem/progenitor cell popula-
tion of fate-restricted potential that feeds the high
cell replacement demands of the adult skeleton.
INTRODUCTION
Complex multicellular organisms depend on mesenchymal cells
to provide an architectural superstructure for the bodywhole and
the organs within it. Yet, a detailed understanding of these cells
is very limited for most tissues with the exception of the muscu-
loskeletal system. There, it is apparent that subpopulations of
mesenchymal cells provide specific functional roles, including
osteolineage cell participation in bone maintenance, bone
marrow function, and metabolic regulation (Lee et al., 2007;
Raaijmakers et al., 2010).CThe existence of multipotent bone marrow stromal cells
(BMSCs), or skeletal/mesenchymal stem cells (SSCs/MSCs,
hereafter MSCs) was proposed based on the identification of
clonogenic populations within the bone marrow that could
differentiate into osteoblasts, chondrocytes, and adipocytes
ex vivo (Caplan, 1991; Friedenstein et al., 1974) and, in some
cases, recapitulate bone and marrow formation upon transplan-
tation of cultured cells (Sacchetti et al., 2007). Similar multipotent
MSCs can be isolated from mouse bone marrow (Morikawa
et al., 2009) or from multiple tissue types in human (Crisan
et al., 2008). These isolated populations have entered clinical
testing to either replace cells in damaged tissues or provide
paracrine signals to modulate injury or immune responses.
However, how such cells perform in vivo and how they contribute
to the homeostasis of tissues in situ remains poorly understood,
and therefore, in vivo clonal analysis of endogenous MSCs is
required.
Cell replacement under homeostatic conditions or after injury
is controlled either by symmetric division of existing mature cells
(Dor et al., 2004) or by differentiation of stem/progenitor cells
(Li and Clevers, 2010). The existence of stem or progenitor cell
populations that can generate skeletal tissues in vivo has been
documented by transplantation of MCAM/CD146+ subendothe-
lial cells from human bone marrow (Sacchetti et al., 2007) or
CD105+Thy1 cells from mouse fetal bone (Chan et al., 2009)
and by lineage tracing of nestin+ bone marrow cells (Me´ndez-
Ferrer et al., 2010). Yet, which osteolineage cells divide and
contribute to skeletal remodeling and repair is unclear. Some
studies indicate that bone-surface osteoblasts are postmitotic
and replaced by unspecified immature cells (Kalajzic et al.,
2008; McCulloch and Heersche, 1988; Owen and MacPherson,
1963), while in development, osteoblasts divide (Dominici
et al., 2009; Maes et al., 2010). Further, blood-borne cells
contributing to bone repair have been suggested by reports of
circulating osteoblasts (Eghbali-Fatourechi et al., 2005; Otsuru
et al., 2008). Therefore, the dynamics of osteolineage cells in
adult animals is an issue of debate.
Population dynamics is of particular interest given recent
findings that osteolineage cells, when perturbed, can result inell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc. 259
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including myelodysplasia and acute myeloid leukemia (Raaij-
makers et al., 2010; Walkley et al., 2007a). These models
suggest that genetic alterations in the microenvironment can
be an initiating lesion in the multistep pathway to cancer, at least
in the bone marrow (Raaijmakers et al., 2010). If osteolineage
cells are long-lived and replace themselves, such a model would
be less likely. In contrast, a stem/progenitor population replen-
ishing short-lived mature cells could provide the scenario for
acquired genetic lesions to affect a larger pool of microenviron-
mental cells, particularly if such cells were capable of transloca-
tion. Here, we define that the latter conditions describe the
kinetics and functional properties of osteolineage cells in adult
mice using engineered strains that enable marking of specific
cells types, including the putative MSC.
RESULTS
Pulse-Chase of Mature Osteoblasts In Vivo
To study the kinetics and fate of functional mature cells, we used
a mouse with the mature osteoblast specific gene, osteocalcin
(Ocn) (Ducy et al., 1996), driving a Cre recombinase andmodified
estrogen receptor (ER) fusion gene. These mice were crossed
with ROSA26-loxP-stop-loxP-EYFP (herein Rosa-YFP) reporter
mice to generate Ocn-Cre-ER+Rosa-YFP+ (herein iOcn) mice
(Figure 1A) where Cre recombinase could be activated in
a cell-stage- and time-dependent manner, the latter by adminis-
tration of 4-hydroxytamoxifen (4-OHT). We administered 4-OHT
to 6- to 8-week-old mice, resulting in loxP-flanked stop
sequence deletion and the constitutive expression of the YFP
reporter gene in mature osteoblasts and their progeny. Immuno-
histochemistry for the reporter detected distinct and quantifiable
YFP+ osteoblasts on the endosteal and periosteal surfaces of
femurs and calvaria from iOcn reporter mice at 14 days after
only two doses of 4-OHT treatment (Figure S1A available online),
confirming the efficiency of our system.
Rapid Turnover of Mature Osteoblasts In Vivo
Intravital, two-photon/confocal hybrid microscopy was used to
visualize, quantify, and track the position of Ocn/YFP+ osteo-
blasts in live animals (Lo Celso et al., 2009) (Figure 1A). Fourteen
days after 4-OHT treatment, we scanned both sides of the
sagittal (S.S.) and coronal (C.S.) sutures, which permitted exam-
ination of 40%–60% of the calvarial cavities of the mouse
(Sipkins et al., 2005) (Figure 1B, left panel). We detected quantifi-
able YFP+ osteoblasts distinct frombonematrix (blue; by second
harmonic generation) and vasculature (red; Q-dot) (Figures 1B
[right] and S1B). To trace the same cells over time, we selected
a specific region based on invariant suture landmarks and
mapped this cavity using four to six consecutive images with
Z-stacks (Figure 1B, L1–L4), sequentially imaging individual
iOcn mice over a 6-month period. Without 4-OHT treatment,
very low or no detectable YFP+ osteoblasts were detected
(1.75 ± 1.5 cells in 660 mm2) (Figure 1C, n = 4). We found
a peak YFP-labeling of endosteal osteoblasts at 14 days
(118 ± 31.4 in 660 mm2, n = 6), followed by a significant decrease
to 50% by 30 days (p < 0.0001), eventually reaching the basal
level by 60 days (Figures 1C, 1D, and S1C). 3D reconstruction of
the Z-stack images showed that themajority of YFP+ osteoblasts260 Cell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc.were individually and discontinuously distributed along the
endosteal surface without clustering (Figure 1C, bottom).
(Note, microvessels vary because the exposure of the skull for
imaging leads to wound responses.) Immunohistochemistry of
selected bones imaged above at day 14 and day 60 confirmed
the results of the in vivo imaging (Figure S1D). In contrast to oste-
oblasts, small, bone-embedded YFP+ osteocytes peaked in
number at 30 days after 4-OHT treatment and then decreased
over time, consistent with existing paradigms whereby some
mature osteoblasts differentiate into osteocytes (Dallas and
Bonewald, 2010) (Figure 1E). Histology of femurs and calvaria
also confirmed the decrease in labeled endosteal and periosteal
osteoblasts, consistent with intravital microscopy (Figures S1D
and S1E).
Despite the continuous decrease in number of Ocn/YFP+ oste-
oblasts, it could be possible that mature osteoblasts proliferate
early after tamoxifen induction. Therefore, we performed anti-
Ki-67 immunohistochemistry with calvarial bones at day 4 and
day 7 after 4-OHT treatment because efficient YFP labeling
begins 2–3 days after tamoxifen induction. In all time points
examined (day 14, data not shown), there was no observable
Ki-67 staining in these cells (n > 200 counted, Figure 1F), demon-
strating that existing osteoblasts turn over rapidly and are contin-
uously replaced by another cell population. Independent exper-
iments using BrdU uptake confirmed these results (Figure S1F).
Because mature osteoblasts were reported to proliferate in
irradiated bones (Dominici et al., 2009), we next examined
whether a distinct type of injury might result in osteoblast prolif-
eration. iOcn mice were crossed with Rosa26-loxP-stop-loxP-
DTR (iDTR, inducible diphtheria toxin receptor) mice. In
Ocn-Cre-ER+Rosa-YFP+iDTR+ trigenic mice (hereafter iOcn/
iDTR), the administration of 4-OHT can induce both YFP and
DTR expression specifically within mature osteoblasts. Injecting
low-dose diphtheria toxin (DT) and tracking Ocn/YFP+ osteo-
blasts, we noted 90% elimination of the labeled cells at
7 days (Figure 1G, right). Control DT-treated iOcn mice without
DTR showed no effect on labeled osteoblasts (data not shown).
The remaining Ocn/YFP+ osteoblasts were evaluated intermit-
tently over a 3 month interval and no increase or clustering of
Ocn/YFP+ osteoblasts was noted (Figure 1G), further demon-
strating that mature osteoblasts do not proliferate.
Osterix+ Osteolineage Cells Are a Transient Source
of Osteoblasts in Adult Mice
Osterix (Osx) is known to be expressed earlier than osteocalcin in
the osteoblast lineage (Rodda and McMahon, 2006). A recent
report showed that osterix-expressing preosteoblasts are the
origin of trabecular osteoblasts and osteocytes in developing
bones (Maes et al., 2010). A similar relationship between cells
was observed in fracture healing (Maes et al., 2010). This popu-
lation is also thought to be important in regulating hematopoiesis
(Raaijmakers et al., 2010; Walkley et al., 2007a). We therefore
examined the expansion and durability of YFP+ cells using
a mouse where the Osx promoter drives a Cre-ER fusion
gene, crossed with Rosa-YFP reporter mice to generate
Osx-Cre-ER+Rosa-YFP+ (herein iOsx) mice (Figures 2A and
S2A). To test whether preosteoblasts contribute to the long-
term maintenance of mature osteoblasts under homeostasis,
we conducted genetic pulse-chase experiments using iOsx
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Figure 1. Mature osteocalcin+ Osteoblasts Turn Over Rapidly In Vivo without Evidence of Proliferation
(A) Preexisting osteoblasts were pulsed and chased using a transgenic mouse (iOcn mouse). YFP was induced by tamoxifen (4-OHT) injection (2 doses) at
4–6 weeks of age and Ocn/YFP+ osteoblasts were tracked by in vivo imaging at the indicated time points.
(B) Intravital microscopy was used to scan a 2 mm3 2mm region (X, Y) of mouse calvarial cavity (red box, left panel and magnification in right panel) in left frontal
bone (F) near the intersection of the coronal (C.S.) and sagittal (S.S.) sutures (left). Bone collagen (blue), Ocn/YFP+ osteoblasts (green), and vasculature (red) in
scanned area weremapped by acquiring a 33 3 grid of 3D stacks (X, Y, Z: 660 mm3 660 mm3 100 mm in depth). Four red boxes (L1–L4; 660 mm2 each) represent
the site of image analysis over time. Diagram represents a simplistic cross section view of the calvarial cavity.
(C) Ocn/YFP+ osteoblasts in L1 position of the same iOcn mouse were tracked at the indicated time points (top). Z-stack images (50–100 mm depth) were
reconstructed for 3D image analysis (bottom).
(D) The average number (L1–L4) of Ocn/YFP+ osteoblasts from different mice were plotted at the indicated times. Each symbol represents an individual mouse
(n = 16, control; n = 4).
(E) Ocn/YFP-labeled osteocytes within superficial calvarial bone from the same mouse in Figure 1C were imaged at several time points.
(F) Proliferation of Ocn/YFP+ osteoblasts (YFP, green) was assessed four (Day 4) or seven (Day 7) days after 4-OHT treatment in the calvarial cavity of iOcnmice by
anti-Ki-67 immunohistochemistry (Ki-67, red). Anti-GFP/YFP staining was used for enhancing YFP signal. Blue, DAPI.
(G) Mature osteoblasts in the calvaria of iOcn/iDTRmice imaged at 14 days (Before DT) or after three daily doses (100 mg/dose) of diphtheria toxin (+DT) or PBS as
a control (DT). The number of labeled osteoblasts was sequentially tracked by intravital microscopy at the indicated time points. Representative consecutive
images (left) and the average numbers of osteoblasts in 4–6 images (660 mm2/each) per mouse (n = 3/group) (right) are shown.
Scale bars are 50 mm (F) or 100 mm (C, E, and G). Data represent at least three independent experiments (F). See also Figure S1.
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Mx1+ BM-MSCs Are Osteolineage Restricted In Vivoreporter mice. Fourteen days after 4-OHT treatment, intravital
microscopy analysis and anti-GFP/YFP immunohistochemistry
revealed that, unlike Ocn/YFP+ mature osteoblasts, most Osx/
YFP+ preosteoblasts were detected in the outer margin andCthe osteogenic front of sutures or bone marrow. Only a small
portion of cells (<20%) were located on the endosteal surface
of marrow cavities (Figures 2A and S2B). Therefore, we selected
a specific region covering the first frontal bone cavity and theell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc. 261
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Figure 2. Osterix+ Preosteoblasts Turn Over Rapidly In Vivo without Evidence of Proliferation
(A) Sequential imaging ofOsterix+ preosteoblasts in iOsx mice induced with tamoxifen (+4-OHT) by injection at 4–6 weeks of age. Osx/YFP+ preosteoblasts were
tracked by in vivo imaging. Scanned area covering the calvarial cavity and sagittal suture in the left frontal bone was mapped by acquiring a 3 3 2 grid of 3D
stacks (X, Y, Z: 2 mm3 1.3 mm3 100 mm in depth). Two red boxes (660 mm2 each) represent the site of image analysis for tracing the number of preosteoblasts
over time. Bone collagen (blue), Osx/YFP+ preosteoblasts (green), and vasculature (red) are shown.
(B and C) Osx-induced preosteoblasts were tracked at the indicated time points by sequential imaging. The average numbers of Osx-induced preosteoblasts
from different mice with (black circle, n = 10) or without (white circle, n = 4) 4-OHT treatment were plotted at the indicated times (C). Error bars, ± SD.
(D) Proliferation of Osx-induced preosteoblasts on the periosteum near a suture (top) or on the endosteal surface (bottom) was assessed by anti-Ki-67 immu-
nohistochemistry (red) fourteen days after 4-OHT treatment. Arrows indicate YFP and Ki-67 double-positive cells (yellow).
(E) Continuous replacement of osteoblasts by new osteoblasts was assessed in iOcnmice 60 days after the first tamoxifen administration (left) andmaintained for
an additional 60 days. Newly labeled osteoblasts in the same position were reimaged at 14 days after the second tamoxifen administration (right) (n = 4).
Scale bars are 20 mm (D) or 100 mm (B and E). Data represent three independent experiments with similar results (D). See also Figure S2.
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Mx1+ BM-MSCs Are Osteolineage Restricted In VivoS.S., located in the left side of the S.S. and C.S. intersection, and
counted the number of Osx/YFP+ preosteoblasts and their
progeny. Tracing of labeled preosteoblasts by sequential
imaging revealed that the average number of Osx/YFP+ cells
increased temporarily at 30 days after induction, but later
decreased, and returned to the basal level at 90 days (Figures
2B and 2C). We confirmed this with anti-GFP/YFP immunohisto-
chemistry on femoral bone, and their differentiation, with anti-
Ocn immunohistochemistry (Figures S2C and S2D). Consistent
with a previous study (Maes et al., 2010), we observed that
distinct Osx/YFP+ cells on the periosteal surface near the suture
were Ki-67+ (Figure 2D). However, the percentage of Ki-67+ cells
within Osx-labeled cells from adult bones was much lower
(1%; 2–3 cells/200 counted, n = 3) than that from developing262 Cell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc.bones (22% ± 3%) (Maes et al., 2010) and, like the Ocn-labeled
cells, there was no durable labeling of Osx-labeled preosteo-
blasts. This result suggests that the osterix-expressing popula-
tion does not represent a self-renewing pool of progenitors.
To confirm that the labeled mature osteoblasts were continu-
ously replaced by new osteoblasts, iOcn mice imaged at day 60
after the first 4-OHT treatment were followed for 2 additional
months and a second sequence of 4-OHT was administered.
At 14 days after the second 4-OHT pulse, imaging the same sites
revealed an increase in the number of Ocn/YFP+ osteoblasts
(Figure 2E). This increase was approximately equivalent to the
number observed at 14 days after the first 4-OHT treatment,
and the numbers again decreased with similar kinetics (data
not shown).
Cell Stem Cell
Mx1+ BM-MSCs Are Osteolineage Restricted In VivoTaken together, these data demonstrate that existing osteo-
blasts and preosteoblasts turn over rapidly and are continuously
replaced by new osteoblasts. If the new osteoblasts were
derived from division of the existing osteoblasts, genetically
labeled 2–3 three months earlier, we would have anticipated
that the portion of labeled cells would remain relatively constant
over this period. Because labeling of osteoblasts instead
required a second activation of Cre recombinase, the new cells
were likely derived from a different cell source that had not previ-
ously expressed the osteoblast markers Ocn and Osx.Long-Term Maintenance of Osteogenic Cells Is
Provided by Progenitors
The myxovirus resistance-1 (Mx1) promoter has been shown to
be activated in bone marrow stromal cells of undefined identity
(Walkley et al., 2007b). In an attempt to define a marker for
more immature osteolineage cells, we assessed Mx1-Cre mice
crossed with Rosa-YFP reporter mice (hereafter Mx1/YFP).
Twenty days after pIpC administration (25 mg/kg every other
day for 10 days) to activate Mx1, we observed YFP labeling in
70% ± 8% of endosteal bone cells (Figures 3A [top] and 3C).
Additional immunohistochemistry with anti-Ocn, anti-osteopon-
tin (expressed by mature osteoblasts; data not shown), and
anti-Osx antibodies confirmed that the Mx1/YFP+ cells on the
endosteal surface of bones were osteogenic cells (Figure 3A,
top middle and right). Because Mx1-inducible cells include
hematopoietic-derived osteoclasts (Walkley et al., 2007b), it is
possible that some of YFP+ bone cells were osteoclasts. To
exclude this possibility and improve specific cell quantification,
we developed trigenic Mx1-Cre+Rosa-Tomato+Ocn-GFP+ mice
(Mx1/Tomato/Ocn-GFP) by crossing Mx1-Cre mice with
Rosa26-loxP-stop-loxP-tdTomato reporter and Ocn-GFP mice,
allowing the distinction between Mx1-induced osteoblasts (red
and green) andMx1 noninducible osteoblasts (green). Flow cyto-
metric analysis showed that 88% of Ocn+ osteoblasts were red
and green at 30 days postinduction (Figure 3B), confirming that
Mx1 labels themajority of endosteal bone cells. Next, to examine
the durable labeling of Mx1 and to eliminate Mx1-inducible
hematopoietic cells, we transplanted wild-type marrow cells
(WT-BMT) into lethally irradiated Mx1/YFP mice and, 8 weeks
later, inducedMx1 activity by pIpC treatment. Over 6–10 months
after labeling (four to five cycles of osteoblast turnover), about
80% of Ocn+ osteoblasts on the endosteal surface in femurs
and calvaria remained YFP+ (Figures 3A [bottom], 3C, and
S3B), indicating that the labeling of osteoblasts by Mx1 is
durable. We observed similar results in nonirradiated, non-WT-
BMT animals (Figure S3A). We confirmed low basal activity of
Mx1-Cre and the specificity of these data by anti-GFP/YFP
and ant-Ocn immunohistochemistry with femurs from the indi-
cated control mice (Figures 3C [pIpC] and S3C). The level of
Mx1-induced hematopoietic cells was less than 1% (6 months)
or undetectable (10 months) in the mice (data not shown),
arguing against a contribution of Mx1-induced osteoclasts to
the endosteal cell population. Comparing osteoblast labeling
with that of the hematopoietic compartment revealed that the
percentage of marked osteolineage cells was similar to the
labeling of LT-HSCs (Kiel et al., 2005) (>95%, Figures S3C and
S3D), but much higher than that of mature hematopoietic cellsC(40%–60%, Figures S3E and S3F), further suggesting that
Mx1-Cre can efficiently label osteogenic stem/progenitors.
Previously, it has been suggested that mesenchymal/osteo-
genic progenitors are located inmidsuture and are critical for cal-
varial bone growth, whereasmore differentiated osteogenic cells
are in the osteogenic fronts of parietal bones (Lana-Elola et al.,
2007). Consistent with this, most of the midsuture mesenchymal
cells from all sutures examined in Mx1/YFP mice were homoge-
neously and durably labeled by the Mx1 promoter, whereas
GFP+ cells labeled by activity of the Col2.3 (an osteoblastic
promoter induced by Osx) and Ocn promoters were detected
only in the osteogenic fronts of the parietal bones (Figure S3G).
In addition, flow cytometric analysis of CD45CD105+ osteo-
genic progenitor fraction (Chan et al., 2009) showed constant
labeling at 40 days after induction (Figure S3C), indicating that
the induction of Mx1 labels endogenous osteogenic stem/
progenitors that can maintain the majority (>80%) of mature
osteoblasts over time in the adult mouse.
Mx1-Induced Progenitors Are Clonogenic and Have
Multilineage Differentiation Potential In Vitro
Others have demonstrated that mesenchymal stem/progenitor
cells are enriched in the Sca1+CD90+ or Sca1+CD140a+ bone
marrow fractions (Chan et al., 2009; Morikawa et al., 2009). We
found that 93% of clonogenic stromal cells were present in the
nonhematopoietic (CD45Ter119CD31) CD105+CD140a+
bone cells (5.4% ± 2.9%, Figure 3D). Further immunophenotypic
analysis revealed that this fraction was similar to the recently
defined Sca1+CD140a+ MSCs, with uniformly high expression
of Sca-1, CD29, CD44, and CD133 and lower expression of
CD90, CD49d, and CD71 (Morikawa et al., 2009) (Figure S3H).
To test whether Mx1-Cre marks this fraction, analysis of Mx1/
YFP mice revealed that 44% ± 9% of the CD105+CD140a+ frac-
tionwas YFP+ and the fractionmarkedwith YFPwas enriched for
80% of the clonogenic cells. The clonogenic frequency of this
fraction is 1 in 20, which is 50-fold higher than that of
CD45Ter119 cells (1/1,000) and 50,000 fold higher than
that of unfractionated bone marrow stromal cells (1/1 3 106
cells) (Figure 3E). Those colonies that emerged from the YFP
fraction were morphologically distinct, resembling what others
have described as endothelial cells (Morikawa et al., 2009).
Using a single pulse of pIpC and in vivo imaging, we defined
that Mx1 labels a majority of osteogenic progenitors and a frac-
tion of Ocn+ mature osteoblasts (Figure S4A), but not osteocytes
(data not shown). However, GFP+ cells from iOcn, iOsx, or
Col2.3-GFP mice comprised <3% of the CD105+CD140a+ frac-
tion and did not form colonies (Figures S4B and S4C). Therefore,
Mx1 induction labels an immature, clonogenic subset of the
CD105- and CD140a-expressing putative MSCs, and by com-
parison with the results of labeling more mature populations,
it can be used to discern MSC function in vivo.
When Mx1-induced progenitors (YFP+CD105+CD140a+
CD45Ter119CD31) were single-cell sorted and cultured,
single Mx1-induced progenitors formed colonies that were
YFP+ (Figure S4D). Cells from a single, dispersed and split
Mx1/YFP+ colony were cultured under differentiation conditions
and demonstrated the ability to become osteoblasts, adipo-
cytes, and chondrocytes at a single-cell level in vitro (Figure 3F).
These analyses indicate that Mx1-labeled colony-forming cellsell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc. 263
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Figure 3. Mx1-Induced Cells Have MSC Characteristics and Maintain Long-Term Repopulation of Osteoblasts In Vivo
(A)Mx1-induced osteogenic cells (YFP+) in calvaria (left) or femur sections (middle and right) of Mx1/YFP mice prepared 20 days after pIpC treatment (day 20) or
6 months after pIpC treatment (at 6–8 weeks after irradiation and wild-type bone marrow transplantation, +WT-BMT) were analyzed by undergoing intravital
microscopy (left, blue, bone; green, Mx1-induced osteoblasts) or by being stained with anti-GFP/YFP (YFP), anti-osterix (Osx, for preosteoblasts), and anti-
osteocalcin (Ocn, for mature osteoblasts) antibodies (right).
(B) Labeling efficiency of osteoblasts byMx1. From collagenase-treated bones of Mx1/Tomato/Ocn-GFP trigenic mice at 30 days after pIpC treatment following
WT-BMT, the percentage of Mx1-induced (Tomato+GFP+) or noninduced (GFP+) osteoblasts was analyzed by flow cytometry.
(C) Percentage of Mx1-induced osteoblasts (YFP+Ocn+) before (pIpC) or after pIpC (+pIpC) treatment as analyzed by anti-GFP/YFP, anti-osteocalcin immu-
nohistochemistry, and FACs of cells from femurs at the indicated time points (n = 5 per group, right panel).
(D) Enrichment of clonogenic stromal cells in the CD105+CD140a+ fraction. From collagenase-treated wild-type bone cells, the nonhematopoietic fraction
(CD45CD31Ter119) was further separated with CD105 and CD140a. Indicated fractions (A, B, and C) were sorted and their clonogenicity was analyzed by
CFU-F assays (>50 cells/colony at 14 days) (right, n = 5).
(E) Mx1-induced labeling in Mx1/YFP mice was examined using the same antibodies and analyzed as in Figure 3D. The percentage of YFP (box A) and YFP+
(box B) within CD105+CD140a+ cells was determined and these fractions were used for CFU-F assays (right, n = 4).
(F) Multilineage differentiation potential of Mx1-induced clones was examined using single-cell-driven, clonally expanded Mx1-induced progenitors (Figure 3E,
box B) that were further incubated with indicated condition medium or MSC medium (Control) for 28 days (n = 8). Cells were stained with Oil-Red for adipocytes
(Adipogenic), Alizarin-Red for osteoblasts (Osteogenic), or Toluidine-blue for chondrocytes (Chondrogenic). NIH 3T3 fibroblasts cultured with conditioned
medium were stained as a control (inserted images).
(G) Eight weeks after lethal irradiation followed by wild-typemarrow transplantation (WT-BMT), Mx1/mTmGmice were treated with five doses of pIpC every other
day. After 90 days of further tracing,Mx1-induced (mGFP+, green) orMx1-noninduced (mTomato+, red) osteoblasts from femur sections were analyzed by anti-
osteocalcin (top right) or by anti-nestin immunohistochemistry (bottom). Red arrow indicatesMx1 and nestin double positive cells. Bone (B), bone marrow (BM),
and osteoblasts (Ob) are indicated. Blue, DAPI (A and G).
Numbers in the histogram indicate the average of 5–10 different analyses; error bars, ± SD (D and E). Scale bars are 20 mm (G). Data represent more than three
independent experiments with comparable results (A and G). See also Figures S3 and S4.
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Cell Stem Cell
Mx1+ BM-MSCs Are Osteolineage Restricted In Vivoare consistent with what others have calledMSCs at a single-cell
level by in vitro analysis.
One limitation of our single reporter system is that the possible
existence of Mx1 MSCs or the increase of their descendents
would not be visualized. To overcome this limitation, we crossed
Mx1-Cre mice with Rosa26-loxP-mTomato-loxP-mEGFP
(mTmG) dual reportermice (hereafterMx1/mTmG). In thismodel,
the mTomato cassette is deleted in theMx1-Cre inducible cells,
allowing the expression of the GFP, whileMx1 noninducible cells
and their progeny express mTomato and remain red. After wild-
type marrow transplantation followed by pIpC treatment and an
additional 90 days of incubation, anti-Ocn immunohistochemical
analysis of femurs showed that the vast majority (>90%) of oste-
oblasts on the endosteal surface and of suture mesenchymal
cells maintained GFP labeling homogenously (Figures 3G [top]
and S3G [right]). The persistence of Mx1/GFP labeling and
absence of dilution by unlabeled cells suggests that Mx1 effi-
ciently labels osteolineage cells and that more immature Mx1
(red) progenitors did not contribute significantly to osteoblastic
homeostasis. A known marker of a rare quiescent MSC popula-
tion capable of multilineage cell production is the cytoskeletal
component nestin (Me´ndez-Ferrer et al., 2010). We found that
most (59%), but not all, nestin+ cells in the bone marrow
were also Mx1/GFP labeled (Figure 3G, bottom). Using a nes-
tin-GFP mouse, we confirmed that nestin+ cells are highly en-
riched in the CD105+140a+ fraction (43%) and that nestin is
also highly expressed in suture mesenchymal cells (Figures
S4E and S4F), similar with Mx1/YFP mouse. Therefore, Mx1/
GFP+ cells overlap with at least a subpopulation of the nestin+
MSCs in the bone marrow.
Limited Lineage Potential ofMx1-Induced MSCs In Vivo
Because Mx1-induced progenitors met the ex vivo criteria for
MSCs, we used these cells to test the potential for such cells
to exert their putative multipotency in vivo. The staining of chon-
drocytes in femurs fromMx1/YFPmice (+pIpC at 6–8weeks age)
by anti-aggrecan antibody revealed no YFP signal in chondro-
cytes in either articular cartilage or the growth plate (data not
shown) at 40 days, 6 months, (Figure 4A), or up to 10 months
(Figure S3B, middle) after pIpC induction. Even when Mx1
activity was induced when bone and cartilage development
was active (P7), no YFP signal was apparent in chondrocytes
(Figure 4A, +pIpC at P7), indicating an absence of in vivo chon-
drogenic potential.
To assess adipocyte potential ofMx1-induced progenitors, we
examined bone marrow and periosteal adipocytes at varying
ages. Despite a more than 10-fold increase of bone marrow
adipocytes as measured by anti-perilipin antibody staining in
old Mx1-induced mice (12 months old with 6 months after
pIpC following 2 months after BMT) as compared with young
Mx1-induced mice (4 months old with 40 days after pIpC),
neither population of mice had >5% of adipocytes marked by
Mx1-Cre (Figures 4B, S5A, and S5B). These data suggest that
adipogenic differentiation of Mx1-induced progenitors in adult
mice is rare despite the generation of new adipocytes in the
bone marrow and the adipogenic capacity of the cells ex vivo.
To further confirm these data, we employed Mx1/mTmG dual
reporter mice, which are described in Figure 3G. Consistent with
the Mx1/YFP model, in vivo imaging of calvaria showed that theCvast majority of osteoblasts on the endosteal surface and of
suture mesenchymal cells maintained mGFP labeling homoge-
nously (Figure 4D, left). Interestingly, many perivascular cells
close to the endosteal surface were labeled with GFP, a site re-
ported by others to be the location of MSCs (Figures 4C and
S5C) (Me´ndez-Ferrer et al., 2010). In addition, immunohisto-
chemical analysis of femurs showed that all chondrocytes,
skeletal muscle cells, fibroblasts, and blood vessels remained
red, supporting the idea that they are functional, butMx1 nonin-
ducible (Figures 4D, S5D, and S5E). Therefore, Mx1 induction
labels MSC-like cells in vivo that are only fated to the osteoline-
age, and not these other cell types, under physiological condi-
tions in the adult mouse skeleton.
Mx1-Induced Osteogenic Stem/Progenitors Are the
Source of New Osteoblasts for Fracture Repair In Vivo
Fracture healing is associated with an increase in local osteo-
blasts (Leucht et al., 2007). However, the origin of new osteo-
blasts in fracture sites has not been clearly demonstrated
(Schindeler et al., 2008). Therefore, to define the source of the
osteoblasts located at injury sites, we generated microfractures
of the calvarium using needle wounding at osteostage-specific
pulse-labeled animals. When Ocn/YFP+ mature osteoblasts
(iOcn mice) and Osx/YFP+ preosteoblasts (iOsx mice) were
tracked for 7 days after injury, they increased in number at the
injury site, but only small numbers were detected by sequential
in vivo imaging (Figures 5A [top] and 5B). In contrast, Mx1-
induced osteogenic cells in Mx1/mTmG mice newly appeared
in the site of the fracture at 2 days and dramatically increased
at 7 days after injury (Figures 5A [bottom] and S6A). Most of the
osteogenic cells at the fracture site wereGFP+ and the number of
Mx1-induced cells at the injury site increased by more than 100-
fold (Figure 5B, square). By anti-Ki-67 immunohistochemistry, no
anti-Ki-67 staining in iOcn mice and rare staining (<3%) in iOsx
mice was evident (Figure S6B). However, >10% ofMx1-induced
osteogenic cells were Ki-67+ in Mx1/mTmG mice (Figure 5C,
top). This fraction was much higher than that in uninjured bones
(<1%; data not shown) and new clusters of Mx1/GFP+ osteo-
genic cells observed at the fracture site stained positively for
Ocn (Figure 5C, bottom), indicating the responsiveness of this
population to physiologic challenge. Of note, these cells did
not stain with anti-CD45 and were therefore not inflammatory
cells that had consumed the GFP dye (Figure S6C). To further
distinguish and enumerate stem/progenitor cells and mature
osteoblasts during fracture healing, we used trigenic Mx1/
Tomato/Ocn-GFP dual reporter mice. In this model, Mx1-
induced stem/progenitors express Tomato and their osteo-
blastic progeny express Tomato and GFP, while mature
osteoblasts from Mx1-noninducible progenitors express GFP
alone. When mature osteoblasts and their progenitors were
tracked for 21 days after injury, Mx1-induced stem/progenitors
(Tomato+) newly appeared in the site of the fracture at
2–5 days and dramatically increased in number at 12 days.
Subsequently, Mx1-labeled stem/progenitors near the fracture
surface differentiated into GFP+ osteoblasts (Figure 5D, day
12, yellow). More importantly, most osteoblasts associated
with new bone (analyzed by second harmonic generation; blue)
at the fracture site were Tomato and GFP double positive, and
there were no observable GFP single positive osteoblasts. Theseell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc. 265
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Figure 4. Mx1-Induced Cells Are Osteogenic Stem/Progenitors and Do Not Contribute to the Maintenance of Other Bone Marrow Mesen-
chymal Cells In Vivo
(A) Femurs from recipient Mx1/YFP mice transplanted with wild-type bone marrow were analyzed before (pIpC) or 20 days after 5 doses of pIpC from postnatal
day 7 (+ pIpC at P7), and 40 days (day 40) or 6 months after five doses of pIpC at 6–8 weeks old (6 months +WT-BMT) forMx1-induced progenitor contribution to
chondrocytes (Ch) in articular cartilage. Sections were stained by anti-GFP/YFP and anti-Aggrecan antibodies (red), respectively. BM, bonemarrow; B, bone; Ob,
osteoblasts.
(B) Mx1-induced progenitor contribution to adipocytes in outer surface (periosteal) or marrow (endosteal) of bones was assessed by immunostaining of femur
sections with anti-GFP/YFP (green) and anti-perilipin antibody (red) and by Oil-Red staining (inserted images). Bones (B), bone marrow (BM), and skeletal muscle
(SM) were indicated. Asterisk indicates adipocytes with lipid droplets.
(C)Mx1-induced progenitors are perivascular and distinct from endothelial cells. Sections from Figure 4D were stained by anti-GFP/YFP (green) and anti-CD31
(red) antibodies.
(D) By using dual reporter mice (mTmG) crossed withMx1-cremice,Mx1+ (green) orMx1 (red) cells were analyzed by intravital microscopy of the calvaria (left) or
by immunohistochemistry of femur sections (Growth plate and Cartilage) and skeletal muscle. Bonemarrow (BM), chondrocyte (Ch), osteoblast (Ob), vessel, and
endothelial cells (En) are indicated. To distinguish fibroblasts, anti-ER-TR7 staining (white) was included. Blue, DAPI (A–D).
Scale bars are 20 mm (C) or 50 mm (A, B, and D). All data represent at least two (A, pIpC) or three independent experiments with consistent results. See also
Figure S5.
Cell Stem Cell
Mx1+ BM-MSCs Are Osteolineage Restricted In Vivoresults demonstrate that the migration and proliferation of
osteogenic progenitor cells labeled by Mx1 supply the majority
of osteoblastic cells participating in fracture healing (Figure 5D,
day 21). Consistently, when microfractures were generated at
distal metaphysis and articular cartilage of femoral bones, the
number ofMx1-labeled periosteal (inner cambial) and endosteal
osteoblasts at the fracture site markedly increased compared to
that in uninjured bones at 21 days after injury (Figure 5E). In addi-266 Cell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc.tion, newly generated chondrocytes during the fracture healing
remainedMx1 (Figure 5E, right, white arrows), further support-
ing the idea that the Mx1-labeled osteogenic stem/progenitors
(OSPCs) are distinct from chondrogenic progenitors.
To test the migration of osteoblasts toward injury in vivo,
continuous Z-stack imaging of individual cells with intravital
microscopy was conducted over 7 hr at 24 hr after injury (Fig-
ure S6D). In addition, we sequentially scanned the detailed
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Figure 5. Migration and Proliferation of Mx1-Induced OSPCs, but Not Differentiated Osteoblasts, Supply the Majority of Osteoblasts in
Fracture Healing
(A) Dramatic relocation of Mx1-induced OSPCs during fracture healing. YFP+ osteoblasts near the injury on iOcn (top) or Mx1/mTmG mouse calvaria (bottom)
were imaged immediately after injury (day 0) and at the indicated times after injury.
(B) The average numbers of Ocn-, Osx- or Mx1-labeled cells within the injury zone were plotted at the indicated time (n > 5 per group). Error bars, ± SD.
(C)Mx1-induced OSPCs were assessed for proliferation by Ki-67 staining (white, top) and differentiation by anti-Ocn (white, bottom) seven days after injury from
Figure 5A. Arrows indicateMx1 and Ki-67 double positive cells (top) andMx1 and Ocn double positive osteoblasts (bottom). Green,Mx1+ cells; red,Mx1- cells;
white, Ki-67+ (top) or Ocn+ (bottom) cells; blue, DAPI.
(D)Mx1-induced OSPCs and osteoblasts at the injury site on Mx1/Tomato/Ocn-GFP mouse calvaria were imaged at the indicated times after injury. An image in
the bottom left corner of the day 2 image indicates osteogenic cells in uninjured bone. Arrows indicate newly translocatedMx1-induced OSPCs (day 5, red) and
osteoblasts derived from Mx1+ OSPCs (day 12 and day 21, yellow). Blue, bone.
(E) Three weeks after injury at distal metaphysis (left) and articular cartilage (right) of femurs in Mx1/YFP mice,Mx1-induced cells and chondrocytes at the site of
microfractures were assessed by immunostaining with anti-GFP/YFP, anti-aggrecan (left), and anti-collagen type II (right, Col II) antibodies and by H&E staining of
parallel sections. White arrows indicate newly generated chondrocytes. B, bone.
(F) Mature osteoblasts assessed for mobility after injury. At 14 days after tamoxifen treatment, Ocn/YFP+ osteoblasts were imaged immediately (0 hr) or 24 hr and
48 hr after injury near (proximal; <400 mm) or over 400 mmaway (distal) from the injury site. Arrows indicate stationary (red) andmigrating (white) osteoblasts. Blue,
bone; green, YFP+ osteoblasts; red, vasculature (Q-dots).
Scale bars are 50 mm (C–F) or 100 mm (A). Data represent three (C and E) or five (A, D, and F) independent experiments (two to four injuries/each experiment) with
comparable results. See also Figure S6.
Cell Stem Cell
Mx1+ BM-MSCs Are Osteolineage Restricted In Vivostructures of bone matrix, osteoblasts, and vessels near the
injury sites immediately (0 hr), 24 hr, and 48 hr after injury (Fig-
ure 5F). We noted that multiple Ocn/YFP+ osteoblasts appeared
to move toward the injury site. We confirmed these results byCZ-stack imaging (Figure S6E). Interestingly, the endosteal Ocn/
YFP+ osteoblasts of the uninjured controls were also observed
to shift position in a manner not explained by the subject’s
breathing or pulse (data not shown).ell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc. 267
AB C
Figure 6. Mx1-Induced OSPCs Are Transplantable by Intravenous Infusion
(A) Sorted Mx1-induced osteogenic stem/progenitors (bottom, 5,000 Mx1+ OSPCs from Figure 3E, box B) or control osteoblasts (top, 5,000 GFP+ cells from
Col2.3-GFPmice) were transplanted intravenously into wild-type mice and were tracked in vivo by intravital microscopy at indicated time points (n = 3 to 5 mice
per each group).
(B) Osteoblast differentiation of transplanted Mx1+ OSPCs in femur sections from (A) (4 months) was tested by anti-osteocalcin staining (n = 3).
(C) Relative homing efficiency of Mx1-induced osteogenic stem/progenitors. Sorted Mx1+ OPCs (5,000) and wild-type LinKit+Sca+CD48CD150+ HSPCs
(5,000) stained with DiD (red) were mixed and transplanted intravenously into wild-type irradiated mice. Twenty-four hours later, the number of cells in bone
marrow of calvaria was counted by intravital microscopy.
An arrow in (A) indicatesMx1+ OSPCs in the bone marrow cavity. Scale bars are 20 mm (B) or 100 mm (A and C). Arrows in (B) indicate differentiated osteoblasts
from donor cells. See also Figure S7.
Cell Stem Cell
Mx1+ BM-MSCs Are Osteolineage Restricted In VivoTransplantation Capability of OSPCs
We next tested whether osteogenic stem/progenitors isolated
from Mx1/YFP mice were capable of translocating by a blood-
borne route. Mx1-induced OSPCs (isolated as in Figure 3E, red
box) from these mice transplanted with wild-type marrow were
isolated by flow cytometry and injected intravenously into nonir-
radiated (Figures 6A [left] and S7A) or sublethally irradiated
(Figures 6A [right] and S7B) wild-type recipients. The Mx1/
YFP+ OSPCs homed to the abluminal surface of sinusoidal
vessels in the bone marrow at day 7, increased in number, and
stably incorporated as bone units on endosteal surfaces for at
least 4 months with over 70% (5/7) engraftment efficiency.
They further differentiated into Ocn+ mature osteoblasts at
multiple sites in femurs (Figure 6B). In contrast, transplantation
of control YFP+CD105+CD140a cells (isolated as in Figure 3D,
box A) from Mx1-induced mice (data not shown) or GFP+ cells
(mature osteoblasts) from Col 2.3kb-GFP mice did not reveal
YFP+ or GFP+ cells on the endosteal surface (Figure 6A, top).
We compared the homing of OSPCs with that of HSPCs
(LKSCD48CD150+) (Kiel et al., 2005) by in vivo imaging of
calvarial bone marrow cavities (Lo Celso et al., 2009) and found
that OSPCs homed to bone marrow with an efficiency of
15%–20% that of HSCs (Figure 6C). Therefore, Mx1-induced268 Cell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc.OSPCs can translocate by vascular spread and engraft at distal
sites.
Functional Capacity of Transplanted Mx1-Induced
OSPCs
Although we observed long-term engraftment and osteoblast
differentiation of transplanted Mx1-induced OSPCs, their func-
tional contribution to recipient bones was not clear. Therefore,
we assessed the in vivo contribution of transplanted OSPCs in
the repair of fractured bone in aged female animals as an assess-
ment of potential in amodel resembling a clinical need. Using the
same number of freshly isolated mature osteoblasts (Col2.3kb-
GFP-labeled) or OSPCs (Mx1-labeled) in matrigel, we trans-
planted cells at the site of mechanical injury and examined
bone repair. We observed engraftment of OSPCs in substantially
increased numbers at the fracture sites (Figure 7A). These cells
differentiated into functional osteoblasts (Ob) and osteocalcin-
expressing osteocytes (Ocy) (Figure 7B, right) producing
a bone bridge and ectopic mineralized bones (Figures 7A
[arrows] and 7B [black squares]) in marked contrast to trans-
plantedmature osteoblasts (Figure 7A, top). We confirmed these
results by anti-type-I collagen immunohistochemistry (data not
shown). Next, to further test their progenitor function, we
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Figure 7. Mx1-Induced OSPCs Contribute to Fracture Healing
(A) The same 5,000 Mx1+ OSPCs (bottom) or Col2.3-GFP+ osteoblasts (top) from Figure 6A were mixed with 20 ml of matrigel and transplanted at the site of
calvarial injury (1 mm diameter) of 1-year-old wild-type female mice (Aged female). Transplanted cells and new bone formation were tracked by sequential
in vivo imaging.
(B) Osteoblast differentiation and new bone formation of transplanted Mx1-induced OSPCs at injury sites (day 21) was assessed by bright field (top left), H&E
(bottom left), and anti-osteocalcin staining (right). Black boxes indicate the sites of newly generated bones byMx1+ osteoblasts (Ob) andMx1+ osteocytes (Ocy)
derived from transplanted Mx1+ OSPCs.
(C) A singleMx1-labeled OSPC from Mx1/Tomato/Ocn-GFP mice was transplanted into the calvarial injury of a wild-type mouse. Clonal expansion, osteogenic
differentiation (Tomato+GFP+), and new bone formation (arrow, blue) were assessed by sequential in vivo imaging at the indicated times.
(D) Engraftment frequency of Mx1+ OSPCs in injury was tracked by sequential in vivo imaging. Numbers at left are input cell number and the frequency of
successful engraftment shown at the right.
(E) Serial transplantation ofMx1+ OSPCs. SortedMx1+ OSPCs (red box on top scatterplot, 1,000 cells/injury, n = 8) were transplanted into injury sites of C57BL/6
recipients. Four weeks later, cells from the injury site were analyzed by in vivo imaging (middle, left), FACs-sorted (red box in middle right scatterplot), and
retransplanted into secondary recipients (100 cells/injury, n = 3). The repopulation ofMx1+ OSPCs at secondary injuries was tracked by sequential in vivo imaging
at indicated time points (bottom).
Arrows in (A) and (C) indicate newly developed bones. Scale bars are 20 mm (B), 50 mm (C, D, and E), or 100 mm (A). Data represent 12 injuries (A) or three (C)
independent experiments with comparable results.
Cell Stem Cell
Mx1+ BM-MSCs Are Osteolineage Restricted In Vivoassessed the clonal dynamics of Mx1-labeled OSPCs. When
single Mx1-labeled OSPCs were isolated, transplanted, and
tracked in vivo, they rapidly generated new progenitors at the
site of injury (Figure 7C, day 7). Later, these cells acquired
features of differentiated osteoblasts (red and green) and
produced mineralized bone (blue) (Figure 7C, day 21), while
some of them remained as progenitors (red). These data indicate
that Mx1-induced OSPCs can be transplanted and functionally
contribute to the recovery of injured bones. When transplanted
at a limiting dilution level, OSPCs rapidly generated new cellsCwith 1 in 40 engraftment efficiency in vivo at the site of injury
(Figure 7D). When Mx1-labeled cells were reisolated at 4 weeks
after transplantation, 33% ± 5% preserved progenitor char-
acteristics and successfully repopulated with secondary trans-
plantation (Figure 7E). These data indicate that Mx1-induced
OSPCs can be transplanted, and that they functionally
contribute to the recovery of injured bones. Further, the stem/
progenitor cells are capable of secondary transplantation, indi-
cating that they can either self-renew or at least be maintained
at the injury site.ell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc. 269
Cell Stem Cell
Mx1+ BM-MSCs Are Osteolineage Restricted In VivoDISCUSSION
The studies presented here clarify the source and lifespan of
osteoblasts in the adult mouse, building on historic work using
morphologic definitions of cells and 3H-thymidine incorporation
in a mixed cell population (Jilka et al., 1998; McCulloch and
Heersche, 1988; Owen and MacPherson, 1963). The use of
genetic tools now permits a more precise definition of the short
lifespan (60 days) and postmitotic state of mature osteo-
blasts, the duration and modest proliferation of preosteoblasts,
and the self-preserving nature and rapid cell cycling of the
osteogenic stem/progenitor cells that maintain life-long osteoli-
neage cells.
The identity and in vivo multipotency of putative MSCs from
various different tissues has been a source of controversy
(Caplan and Correa, 2011). TheMSC asmost commonly defined
is a cell with CFU-F and multilineage differentiation potential
in vitro. Our data indicate thatMx1-induced cells satisfy the char-
acteristics of what has been termed an MSC by immunopheno-
type, clonogenic capacity, single cell-derived multilineage differ-
entiation capability ex vivo, and in vivo osteogenic differentiation
and new bone formation after transplantation. These bone
marrow cells appear to be a subset of the generally quiescent
nestin+ cells that contribute to the HSC niche (Me´ndez-Ferrer
et al., 2010) and may not reflect all of the different cell popula-
tions that have been termed ‘‘MSCs’’ and studied by others.
The Mx1-induced cells are predominantly osteolineage
restricted with only a minimal amount of adipocytic cell marking
with lineage tracing and are more consistent with a skeletal stem
cell as proposed by Bianco et al. than a broadly defined MSC
(Bianco et al., 2008). Whether the adipocytes derived in vivo
from bipotential Mx1-induced cells or a distinct subset within
the Mx1-induced pool cannot be determined. However, our
data clearly demonstrate that Mx1-induced cells do not label
chondrocytes both under homeostatic and after fracture injury
in vivo, a population that has been shown to be a descendent
of nestin-labeled cells (Me´ndez-Ferrer et al., 2010). These data
imply that Mx1-induced OSPCs do represent a distinct and not
entirely overlapping subset of nestin+ cells, suggesting the
possible heterogeneity of nestin+ cells in bone marrow with
distinct lineage capability.
The bone healing mechanism and the source of new osteo-
blasts in fracture sites have been long controversial (Schindeler
et al., 2008). Mx1-induced OSPCs are responsive to stress
conditions and fracture in contrast to Osx-labeled or Ocn-
labeled osteoblasts. By the sequential imaging of fracture sites
in Mx1 and Ocn dual reporter mice, osteogenic progenitors
were shown to appear at the site of injury as early as 2 days after
injury and proliferate, with the cells close to the fracture differen-
tiating into functional osteoblasts. In addition, the absence of
distinct osteoblasts that failed to label withMx1 within the injury
indicates thatMx1-labeled OSPCs are the source of new osteo-
blasts during fracture healing (Figure 5D). Although we did not
test whether OSPCs circulate under physiologic conditions, as
reported by others (Otsuru et al., 2008), we observed that they
are capable of translocating locally and via the vasculature by
transplantation. Taken together, our data demonstrate that the
contribution of this subset of putatively multipotent BMSCs to
bone regeneration and repair is very lineage limited in adult270 Cell Stem Cell 10, 259–272, March 2, 2012 ª2012 Elsevier Inc.animals in vivo and that Mx1 labels an osteolineage stem/
progenitor population.
The ability of proliferating, durable stem/progenitor cells to
replace short-lived mature cells and to translocate to local and
distant sites poses an interesting possibility for their involvement
in disease. The prior studies indicate that altered marrow micro-
environmental cells can induce hematopoietic disease (Raaij-
makers et al., 2010; Walkley et al., 2007a), giving them a greater
potential as a disease mechanism based on the findings here.
Inherited genetic syndromes (such as Schwachmann-Diamond
Syndrome) are plausibly associated with a broad-based defect
in hematopoietic support on the basis of skeletal defects as sug-
gested by prior studies deleting the disease-associated gene
(Sbds) selectively in preosteoblasts (Raaijmakers et al., 2010).
Contributions to acquired disease would be in question if mature
cells turned over rarely and were replaced by mature cell divi-
sion. If mature cells turn over rapidly and are replaced by an
amplifying pool of stem/progenitors, the likelihood that acquired
genetic lesions in that primitive pool could persist, accumulate,
and yield large numbers of mature cells increases. The genetic
pulse-chase studies of endogenous osteolineage stem/progen-
itors presented here provide data that such a population exists
in vivo, is replicative, and is responsible for dynamically replacing
the short-lived osteolineage in homeostasis or after injury.
Further, these cells can translocate, indicating their potential to
have a more systemic effect than would be expected from
a highly locally constrained pool. Together, our studies indicate
that mesenchymal cells in bone and bone marrow have a hierar-
chical organization of long-term repopulating progenitors
serving to replace short-lived, postmitotic, mature cells, similar
to tissues such as the blood, skin, and intestine.
To be clear, we point out that the cells we have studied here
are a subset of mesenchymal cells in the bone marrow. They
may not reflect the behavior of putative MSCs from other tissues
or other bone marrow subsets of mesenchymal cells. There may
indeed by true multipotent mesenchymal stem cells (such as
some of the nestin-expressing cells). However, our data indicate
that multipotentcy ex vivo should be regarded with caution, as it
is not a reliable guide as to how the cells will function in vivo. The
Mx1+ subset of BMSCs is, in vivo, an osteolineage-restricted
stem/progenitor cell subset.
EXPERIMENTAL PROCEDURES
Mice
Six- to eight-week-old C57BL/6 mice, Mx1-Cre (B6.Cg-Tg(Mx1-cre)1Cgn/J),
Rosa26-loxP-stop-loxP-EYFP (Rosa-YFP, B6.129X1-Gt(ROSA)26Sortm1(EYFP)
Cos/J), Rosa26-loxP-stop-loxP-tdTomato (Rosa-Tomato, B6.Cg-Gt(ROSA)
26Sortm9(CAG-tdTomato)Hze/J), Rosa26-loxP-stop-loxP-DTR (iDTR) (Buch et al.,
2005), and Rosa26-loxP-mTomato-loxP-mEGFP (mTmG, B6.129(Cg)-
Gt(ROSA)26Sortm4(ACTB-tdTomato–EGFP)Luo/J) were purchased from Jackson
laboratory. Col2.3-GFP, Ocn-GFP, Osx-Cre-ER (Maes et al., 2010) and Ocn-
Cre-ER (C57BL/6 background) mice were provided by author H.M.K. The
induction of iDTR andMx1 is described in Supplemental Experimental Proce-
dures. All mice were maintained in pathogen-free conditions, and all proce-
dures were approved by Institutional Animal Care and Use Committee
(IACUC).
In Vivo Imaging
To image YFP+ osteoblasts and osteogenic progenitors in vivo, indicated mice
were anesthetized and prepared for a custom-built two-photon and confocal
Cell Stem Cell
Mx1+ BM-MSCs Are Osteolineage Restricted In Vivohybrid microscope specifically designed for live animal imaging as described
previously (Sipkins et al., 2005) (Lo Celso et al., 2009). Briefly, to trace the
change in osteoblast number over time, the injured site or the first frontal
bone cavity located in the upper left side of the S.S. and C.S. intersection
was mapped by four to six consecutive images (660 mm2/image), which
covered most of the endosteal osteoblasts (YFP), the vessel network
(Q-dots), and the bone structures (second harmonic generation by multi-
photon laser) in the cavity. Each image was recorded by Z-stacks with
50–100 mm depth from bone surface and 2 mm interval. Details in intravital
microscopy are described in Supplemental Experimental Procedures. 3D
images were reconstructed using Nikon NIS-Elements software, and osteo-
blast numbers were counted. A two-tailed type 2 t test was applied to all
data. p < 0.05 was considered statistically significant.
Creation of Microfractures and Live Animal Imaging after Injury
For live imaging of osteoblasts near injury, a small incision was introduced on
the scalp of indicated mice, and two separate microfractures were generated
by a 25G or a 27G needle drilling on the surface of calvaria near the intersection
of the S.S. and C.S. Ocn/YFP+, Osx/YFP+, Mx1/YFP+, or Mx1/Tomato cells
near the injury were tracked by sequential in vivo imaging at the indicated
time points. Separately, a small incision was introduced on the right knee
and two separate microfractures were generated by needle drilling (20G) at
distal metaphysis and articular cartilage of femurs of wild-type marrow-trans-
planted and pIpC-treatedMx1 reporter mice. Three weeks after injury, injured
and uninjured (control) femurs were analyzed by immunofluorescence staining
using the indicated antibodies and hematoxylin and eosin (H&E) staining.
In Vivo Imaging of Transplantated Osteogenic Stem/Progenitors
Mx1/YFP+ OSPCs (CD45Ter119CD31CD105+CD140a+YFP+) from lethally
irradiated Mx1/YFP mice or GFP+ cells from Col2.3-GFP mice were FACS
sorted. The sorted cells (5,000 cells/mouse) in 200 ml of PBSwere transplanted
intravenously into wild-type mice, or the indicated number of sorted cells
mixed with 20 ml of matrigel (BD Biosciences) were transplanted upon calvarial
injury of normal (for limiting dilution assay) or 1-year-old wild-type female
mice (for ectopic bone formation). To measure in vivo homing ability of osteo-
genic stem/progenitors, 1,000 sorted Mx1+ OSPCs and 1,000 sorted HSCs
(DiD-stained) were mixed and transplanted into irradiated mice. The implanta-
tion of donor cells at the sites of injury was analyzed by in vivo imaging and
immunofluorescence staining.
Isolation and Flow Cytometry Analysis of Osteoprogenitor Cells
Isolation of osteoprogenitors from compact bones was done by following
mouse mesenchymal progenitor isolation protocols from STEMCELL technol-
ogies. Details are described in the Supplemental Experimental Procedures.
CFU-F, Ex Vivo Multilineage Differentiation, and
Immunofluorescence
Details are described in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes seven figures and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.stem.2012.02.003.
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